Summary Keywords glaucoma, GLP-1 receptor agonists, antidiabtics, ophthalmology, neuroprotection, neurodegenerative diseases Citation Mouhammad ZA, Vohra R, Horwitz A, Thein A-S, Rovelt J, Cvenkel B, Williams PA, Azuara-Blanco A and Kolko M (2022) Glucagon-Like Peptide 1 Receptor Agonists Potential Game Changers in the Treatment of Glaucoma
Each step has built upon the previous, with researchers learning how to harness multiple hormonal pathways simultaneously
Stromal cell signaling Cancer progression must involve both genetic and behavioral changes in cancer cells, and these changes are in part driven by the cancer-associated stromal cells and tumor microenvironment [298, 299]
Additionally, some patients may qualify for clinical trials, which can provide access to new medications at reduced or no cost
Attia, Y
The peptide promotes T-cell proliferation and differentiation, potentially supporting the regulatory T cell populations that are deficient in autoimmune conditions